Thymosin Alpha-1 Dosage and Protocol

At a Glance

Protocol Table: Dose, Route, Timing and Basis

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

One row per use case. Basis: Label (licensed product information), Trial (published human study, PMID), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only).

Why the sepsis trial dosed twice a day: thymosin alpha-1 has a short half-life, and the investigators chose 1.6 mg every 12 hours for one week after an earlier study had found 1.6 mg once daily ineffective. Even at that intensity it did not lower 28-day mortality.

Technique, reconstitution and storage are in the peptide injection guide.

What Is the Correct Dose of Thymosin Alpha-1?

This is one of the few articles in our peptide series where I can give you a dose with genuine confidence. Unlike BPC-157 or TB-500, where all dosing is extrapolated from animal data, thymosin alpha-1 immune therapy has been through formal pharmaceutical development, randomised trials, and licensing as a medicine in some countries.

The standard dose is 1.6 mg administered subcutaneously. This dose was established through the clinical development of thymalfasin (Zadaxin) by SciClone Pharmaceuticals and has been used across clinical trials for hepatitis B, hepatitis C and immune support. Cancer trials also tested higher doses: a randomised melanoma trial of 488 patients compared 1.6, 3.2 and 6.4 mg [6].

This does not mean the dose is perfect for every application or every patient, and a well-defined dose is not the same as proven benefit (see What the Evidence Shows below). But it means we are working from a substantially stronger evidence base than is typical in peptide therapy. Here is what the evidence shows about how to use it.

What Thymosin Alpha-1 Is and What It Does

The thymus is where T cells mature. It shrinks steadily with age, and that decline is one strand of immune aging. Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide that was isolated from thymic tissue as the factor that restored immune function in thymectomised mice. It acts on dendritic cells through Toll-like receptors, which shifts cytokine production and T-cell responses [1]. In laboratory models it also activates an enzyme pathway in dendritic cells (tryptophan catabolism via IDO) that favours a regulated, tolerance-preserving immune environment rather than simple stimulation [2].

That dual profile, more immune activity against pathogens with a built-in brake on inflammation, is why Ta1 was tested in chronic viral hepatitis, as an add-on to vaccination in older adults [3], in cancer care and later in sepsis and COVID-19.

Pharmacokinetics: What Happens After Injection

The relatively short plasma half-life (approximately 2 hours) might seem inconsistent with twice-weekly dosing. However, Ta1’s biological effects — particularly its impact on T-cell maturation and dendritic cell function — persist far longer than its plasma presence. This is because Ta1 triggers intracellular signaling cascades (through Toll-like receptor activation) that continue to influence immune cell behavior for days after the peptide has been cleared from circulation.

Think of it this way: Ta1 is the ignition key, not the fuel. It starts processes that continue after the key is removed.

Standard Dosing Protocols

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Chronic Immune Support

This is the most commonly used protocol for general immune modulation strategies, chronic infection management, and long-term immune optimization:

Acute Immune Support

For acute situations — active infection, perioperative immune support, or the initiation phase of treatment for severe immune compromise:

For context: the largest acute-use trial, TESTS in sepsis, gave Ta1 subcutaneously every 12 hours for 7 days and found no difference in 28-day mortality versus placebo [4].

Cancer Adjunct Protocol

When used alongside chemotherapy, radiation, or immunotherapy:

During active chemotherapy, some protocols increase frequency to daily injections during the immunosuppressive nadir (typically days 7-14 after chemotherapy administration). This intensification targets the period of maximum immune vulnerability. Ta1 should never replace oncologic treatment, and any adjunct should be agreed with the treating oncologist.

For more on the cancer application, see Thymosin Alpha-1 for Cancer: Immunotherapy Support.

Hepatitis B/C Protocol (Licensed Indication)

For reference, the protocol in countries where Zadaxin is licensed (check the national product information, which takes precedence):

Administration Technique

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Injection Protocol

1. Ta1 is supplied as a lyophilized powder (Zadaxin) or as pre-made compounded preparations
2. If lyophilized, reconstitute with 1 mL sterile water for injection
3. Inject subcutaneously in the upper arm, anterior thigh, or abdomen
4. Rotate injection sites
5. Store reconstituted peptide refrigerated (2-8°C); use within 24 hours if using sterile water (not bacteriostatic water)

For the general technique, see How to Inject Peptides.

Timing

There is no strong evidence favoring a specific time of day for Ta1 injection. Some clinicians prefer morning administration, hypothesizing that immune activation during daytime may align better with circadian immune rhythms. In practice, consistency of timing matters more than the specific time chosen.

Dose Adjustments

Body Weight

The 1.6 mg dose is a flat dose, not weight-adjusted. This is the dose used in clinical trials across a range of body weights. The rationale is that Ta1’s mechanism — triggering immune signaling cascades — operates through a threshold effect rather than a concentration-dependent effect. Once the signaling threshold is reached, additional peptide does not proportionally increase the response.

That said, for patients at the extremes of body weight:

Renal Impairment

Ta1 is eliminated renally via proteolytic degradation. In patients with significant renal impairment (GFR below 30), clearance may be reduced. Formal dose-adjustment guidelines for renal impairment have not been established. A common approach is standard dosing with more frequent monitoring in moderate renal impairment, and nephrology input for severe impairment.

Hepatic Impairment

Hepatic metabolism plays a minor role in Ta1 clearance, and the peptide has been used extensively in patients with hepatic disease (hepatitis B and C, hepatocellular carcinoma). No dose adjustment for hepatic impairment is typically needed.

Combination Protocols

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

With Other Immune Peptides

These combinations come from clinical practice, not from controlled trials. LL-37 and TB-500 are unapproved substances (see Regulatory Status).

With Conventional Immunotherapy

Ta1 is being studied in combination with checkpoint inhibitors (anti-PD-1, anti-CTLA-4). The rationale is mechanistic synergy — Ta1 enhances T-cell function while checkpoint inhibitors remove inhibitory signals. Combination dosing follows the standard Ta1 protocol (1.6 mg twice weekly) alongside the scheduled immunotherapy regimen.

Duration of Treatment

How Long Should You Take Ta1?

This depends on the indication:

For long-term use, quarterly monitoring of immune parameters (CD4/CD8 ratio, NK cell function and CD57 counts, total lymphocyte count) helps determine whether continued treatment is providing measurable benefit. If immune parameters have normalized and remain stable after discontinuation, a rest period may be appropriate.

What the Evidence Shows

Preclinical

Animal and cell studies consistently show effects on dendritic cells, T-cell subsets and cytokine profiles [1][2]. These are mechanistic findings. They tell us Ta1 is biologically active, not that a patient will feel better or live longer.

Human trials

The sepsis trial is the most important result here. It was large, blinded and placebo-controlled, and it answered a clear question with a clear “no”. The hepatitis B data, which underpin the licences, are in the review authors’ words too uncertain to say whether Ta1 changes outcomes that matter to patients [5]. Uses such as chronic Lyme, long COVID or healthy aging rest on mechanism and observation, not on controlled outcome data. That is worth knowing before you commit to months of injections.

What Makes Ta1 Dosing Different from Other Peptides

I want to highlight why the dosing confidence for Ta1 is fundamentally different from other peptides in this series:

1. Pharmaceutical development — Ta1 went through formal clinical development as thymalfasin, including human pharmacokinetic work
2. Licensed dosing regimen — the 1.6 mg dose is the licensed dose in the countries where Zadaxin is approved
3. Consistent dose across most trials — 1.6 mg is the dose in the hepatitis, vaccine and sepsis trials; cancer trials also tested 3.2 and 6.4 mg [6]
4. Pharmaceutical manufacturing standards — Zadaxin is manufactured to GMP standards, unlike compounded or “research” peptide preparations

This does not mean the dose is optimized for every possible application, and it does not mean the benefit is proven for every use. But it means the dosing foundation is substantially more evidence-based than extrapolated animal dosing.

Known and Theoretical Risks

• In trials: Ta1 has generally been well tolerated. In TESTS no safety outcome differed from placebo [4]; the Cochrane review rated the evidence on serious adverse events as low certainty [5].
• Autoimmune disease: a drug intended to shift immune activity carries a theoretical risk of aggravating autoimmune conditions. This has not been well studied.
• Unapproved products: the FDA states that compounded Ta1 “may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities”, and that the available safety information is inadequate to understand the extent of any safety issues. Purity, sterility and actual peptide content of research-grade material are unknown, so a stated dose may not reflect what is in the vial.
• Self-injection: non-sterile handling of injectable products risks local and systemic infection.
• Opportunity cost: using Ta1 in place of proven treatment for hepatitis B, cancer or a serious infection is the biggest practical risk.

Regulatory Status

• FDA (US): thymalfasin is not an FDA-approved drug. On the FDA page listing bulk substances that may present significant safety risks in compounding (content current as of 22 April 2026), Ta1 appears among substances previously in category 2 whose nominations were withdrawn by the nominators. It is not on the 503A bulks list and not in category 1 (“under evaluation”) on the FDA list updated 14 May 2026.
• EMA / Germany: not authorised by the EMA or by Germany’s BfArM. A vial marked “research use only” is still unapproved, and its contents have not been tested for human use.
• Elsewhere: licensed as Zadaxin in some countries, mainly for chronic hepatitis B. Check the national product information.
• WADA 2026: not named; anything without regulatory approval in the athlete’s jurisdiction can fall under S0. Athletes should ask their anti-doping organisation.

When to Talk to a Physician

Talk to your doctor before considering Ta1 if you have chronic hepatitis B or C, cancer, a recurrent or chronic infection, or an immune deficiency. Bring the question you want answered (“Is there a licensed treatment with better evidence for my situation?”) and any lab work. If you live in a country where Zadaxin is licensed, your prescriber will use the official product information. Clinical trials (clinicaltrials.gov, the EU Clinical Trials Register) are another route.

Seek care promptly for fever, spreading redness or pain at an injection site, or any new autoimmune symptoms.

The Bottom Line

Thymosin Alpha-1 is dosed at 1.6 mg subcutaneously, typically twice weekly for chronic use, with daily or twice-daily front-loading for a few days in acute use. That dose comes from pharmaceutical development and the licensed product — a rare level of dosing certainty in the peptide space. Duration depends on the indication, ranging from 2-4 weeks for acute infections to indefinite maintenance for chronic immune deficiency, and monitoring immune parameters helps guide treatment duration and reassessment. Be clear-eyed about benefit, though: the best recent evidence showed no mortality benefit in a large sepsis RCT and only very low-certainty evidence in hepatitis B.

For the cancer-specific application, see Thymosin Alpha-1 for Cancer: Immunotherapy Support. For the full overview, see Thymosin Alpha-1: Immune Modulation Deep Dive.

Related Reading

• BPC-157 Dosage Guide: Subcutaneous, Oral, and Injection Protocols
• CJC-1295/Ipamorelin Dosage: Growth Hormone Protocol